Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 102-110 , January 2006

Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-Leukemia Reaction? A Prospective Phase II Study

Presented in part at the Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003

  • Yves Chalandon

      Affiliations

    • Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • Corresponding Author InformationCorrespondence and reprint requests: Yves Chalandon, MD, Hematology Service, University Hospital of Geneva, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland.
    • ,
  • Eddy Roosnek

      Affiliations

    • Immunology and Allergology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Bernadette Mermillod

      Affiliations

    • Medical Informatics Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Laurent Waelchli

      Affiliations

    • Oncology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Claudine Helg

      Affiliations

    • Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland
    • ,
  • Bernard Chapuis

      Affiliations

    • Hematology Service, Department of Internal Medicine University Hospital, Geneva, Switzerland

Received 29 June 2005 ,Accepted 16 September 2005.

References 

  1. Armitage JO . Bone marrow transplantation . N Engl J Med . 1994;330:827–838
  2. Bearman SI , Appelbaum FR , Buckner CD , et al.   Regimen-related toxicity in patients undergoing bone marrow transplantation . J Clin Oncol . 1988;6:1562–1568
  3. Clift RA , Buckner CD , Appelbaum FR , et al.   Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase (a randomized trial of two irradiation regimens) . Blood . 1991;77:1660–1665
  4. Clift RA , Buckner CD , Appelbaum FR , et al.   Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission (a randomized trial of two irradiation regimens) . Blood . 1990;76:1867–1871
  5. Anderson JE , Appelbaum FR , Fisher LD , et al.   Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome . Blood . 1993;82:677–681
  6. Ringden O , Ruutu T , Remberger M , et al.   A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia (a report from the Nordic Bone Marrow Transplantation Group) . Blood . 1994;83:2723–2730
  7. Storb R , Etzioni R , Anasetti C , et al.   Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia . Blood . 1994;84:941–949
  8. Mehta J , Powles R , Horton C , et al.   Bone marrow transplantation for primary refractory acute leukaemia . Bone Marrow Transplant . 1994;14:415–418
  9. Bjorkstrand BB , Ljungman P , Svensson H , et al.   Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma (a retrospective case-matched study from the European Group for Blood and Marrow Transplantation) . Blood . 1996;88:4711–4718
  10. Soiffer RJ , Fairclough D , Robertson M , et al.   CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission . Blood . 1997;89:3039–3047
  11. Mehta J , Powles R , Singhal S , et al.   Autologous bone marrow transplantation for acute myeloid leukemia in first remission (identification of modifiable prognostic factors) . Bone Marrow Transplant . 1995;16:499–506
  12. Ferrara JL , Deeg HJ . Graft-versus-host disease . N Engl J Med . 1991;324:667–674
  13. Prentice HG , Blacklock HA , Janossy G , et al.   Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients . Lancet . 1984;1:472–476
  14. Waldmann H , Polliak A , Hale G , et al.   Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1) . Lancet . 1984;2:483–486
  15. Martin PJ , Hansen JA , Buckner CD , et al.   Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts . Blood . 1985;66:664–672
  16. Martin PJ , Hansen JA , Torok-Storb B , et al.   Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants . Bone Marrow Transplant . 1988;3:445–456
  17. Goldman JM , Gale RP , Horowitz MM , et al.   Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion . Ann Intern Med . 1988;108:806–814
  18. Sehn LH , Alyea EP , Weller E , et al.   Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia (impact of donor lymphocyte infusion) . J Clin Oncol . 1999;17:561–568
  19. Hale G , Zhang M-J , Bunjes D , et al.   Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection . Blood . 1998;92:4581–4590
  20. Korbling M , Przepiorka D , Huh YO , et al.   Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma (potential advantage of blood over marrow allografts) . Blood . 1995;85:1659–1665
  21. Bensinger WI , Weaver CH , Appelbaum FR , et al.   Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor . Blood . 1995;85:1655–1658
  22. Schmitz N , Dreger P , Suttorp M , et al.   Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) . Blood . 1995;85:1666–1672
  23. Bensinger WI , Clift R , Martin P , et al.   Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies (a retrospective comparison with marrow transplantation) . Blood . 1996;88:2794–2800
  24. Schmitz N , Bacigalupo A , Hasenclever D , et al.   Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia (first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation) . Bone Marrow Transplant . 1998;21:995–1003
  25. Powles R , Mehta J , Kulkarni S , et al.   Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases (a randomised trial) . Lancet . 2000;355:1231–1237
  26. Blaise D , Kuentz M , Fortanier C , et al.   Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia (a report from the Societe Francaise de Greffe de Moelle) . J Clin Oncol . 2000;18:537–546
  27. Bensinger WI , Martin PJ , Storer B , et al.   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers . N Engl J Med . 2001;344:175–181
  28. Champlin RE , Schmitz N , Horowitz MM , et al.   Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT) . Blood . 2000;95:3702–3709
  29. Schmitz N , Beksac M , Hasenclever D , et al.   Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia . Blood . 2002;100:761–767
  30. Couban S , Simpson DR , Barnett MJ , et al.   A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies . Blood . 2002;100:1525–1531
  31. Ringden O , Labopin M , Bacigalupo A , et al.   Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia . J Clin Oncol . 2002;20:4655–4664
  32. Korbling M , Anderlini P . Peripheral blood stem cell versus bone marrow allotransplantation (does the source of hematopoietic stem cells matter?) . Blood . 2001;98:2900–2908
  33. Slavin S , Or R , Weiss L , et al.   Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1 . Adv Exp Med Biol . 1985;186:813–818
  34. Hale G , Cobbold S , Waldmann H . T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation . Transplantation . 1988;45:753–759
  35. Hale G , Waldmann H . Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection . Bone Marrow Transplant . 1996;17:305–308
  36. Naparstek E , Or R , Nagler A , et al.   T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse . Br J Haematol . 1995;89:506–515
  37. Naparstek E , Delukina M , Or R , et al.   Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies . Exp Hematol . 1999;27:1210–1218
  38. Barge RM , Brouwer RE , Beersma MF , et al.   Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation (effect of stem cell source on short- and long-term outcome) . Bone Marrow Transplant . 2001;27:1053–1058
  39. Chakrabarti S , Macdonald D , Hale G , et al.   T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival . Br J Haematol . 2003;121:109–118
  40. Bieri S , Helg C , Chapuis B , Miralbell R . Total body irradiation before allogeneic bone marrow transplantation (is more dose better?) . Int J Radiat Oncol Biol Phys . 2001;49:1071–1077
  41. Kottaridis PD , Milligan DW , Chopra R , et al.   In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation . Blood . 2000;96:2419–2425
  42. Storb R , Pepe M , Anasetti C , et al.   What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? . Blood . 1990;76:1037–1045
  43. Storb R , Deeg HJ , Whitehead J , et al.   Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia . N Engl J Med . 1986;314:729–735
  44. Glucksberg H , Storb R , Fefer A , et al.   Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors . Transplantation . 1974;18:295–304
  45. Einsele H , Ehninger G , Hebart H , et al.   Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation . Blood . 1995;86:2815–2820
  46. Attal M , Huguet F , Rubie H , et al.   Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin (a prospective, randomized trial) . Blood . 1992;79:2834–2840
  47. Chalandon Y , Roosnek E , Mermillod B , et al.   Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation . Biol Blood Marrow Transplant . 2004;10:347–354
  48. Kaplan EL , Meier O . Nonparametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457–481
  49. Korngold R , Leighton C , Manser T . Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation . Transplantation . 1994;58:278–287
  50. OKunewick JP , Kociban DL , Machen LL , Buffo MJ . The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia . Bone Marrow Transplant . 1991;8:445–452
  51. Truitt RL , Atasoylu AA . Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow . Bone Marrow Transplant . 1991;8:51–58
  52. Kernan NA , Collins NH , Juliano L , Cartagena T , Dupont B , O’Reilly RJ . Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease . Blood . 1986;68:770–773
  53. Verdonck LF , Dekker AW , de Gast GC , van Kempen ML , Lokhorst HM , Nieuwenhuis HK . Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft . Blood . 1994;83:3090–3096
  54. Cornelissen JJ , van der Holt B , Petersen EJ , et al.   A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies . Exp Hematol . 2003;31:855–864
  55. Johnson BD , Truitt RL . Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease . Blood . 1995;85:3302–3312
  56. Morris EC , Rebello P , Thomson KJ , et al.   Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations (relevance for early adoptive immunotherapy and infectious complications) . Blood . 2003;102:404–406
  57. Schaap N , Schattenberg A , Bar B , Preijers F , van de Wiel van Kemenade E , de Witte T . Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions . Leukemia . 2001;15:1339–1346
  58. Barrett AJ , Mavroudis D , Tisdale J , et al.   T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect . Bone Marrow Transplant . 1998;21:543–551
  59. Sullivan KM , Storb R , Buckner CD , et al.   Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms . N Engl J Med . 1989;320:828–834
  60. Mackinnon S , Papadopoulos EB , Carabasi MH , Reich L , Collins NH , O’Reilly RJ . Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia (is T cell dose important in determining biological response?) . Bone Marrow Transplant . 1995;15:591–594
  61. Drobyski WR , Keever CA , Roth MS , et al.   Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation (efficacy and toxicity of a defined T-cell dose) . Blood . 1993;82:2310–2318
  62. Kolb HJ , Schattenberg A , Goldman JM , et al.   Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia . Blood . 1995;86:2041–2050
  63. Druker BJ , Talpaz M , Resta DJ , et al.   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia . N Engl J Med . 2001;344:1031–1037

PII: S1083-8791(05)00674-9

doi: 10.1016/j.bbmt.2005.09.010

Biology of Blood and Marrow Transplantation
Volume 12, Issue 1 , Pages 102-110 , January 2006

Article Tools

* Image Usage & Resolution